The clinical trial environment faced a massive disruption in the wake of COVID-19, the scope of which was both unprecedented and incalculable. Clinical trial operators were in triage mode. There was no tested playbook for a pandemic, no standard operating procedure. And almost everything depended on sites. So how will clinical trial stakeholders continue to adapt in a (post-) pandemic world?